A tumble in the U.K.

A tumble in the U.K.

CTP slipped 289p to 341p on 7.2 million shares on Wednesday after a Phase III trial of a monoclonal antibody licensed by Chiron(CHIR) to Bayer was not effective in reducing mortality in septic shock patients (see A5). CTP had European marketing rights to the compound, and, more importantly, had a second generation MAb that hinged on the success of CHIR's antibody. Despite the sell-off CTP's market cap remains

Read the full 734 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers